Please login to the form below
Amylin
This page shows the latest Amylin news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and its diabetes plans
This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the long-acting exenatide franchise (Byetta and
Latest news
-
AstraZeneca bullish on diabetes franchise fortunes
This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the exenatide franchise (Byetta and Bydureon).
-
FDA approves Lilly’s GLP-1 diabetes drug Trulicity
However, Lilly and Amylin mutually agreed to end their diabetes alliance in 2011, passing full control of the franchise to Amylin. ... The diabetes alliance of Bristol-Myers Squibb (BMS) and AstraZeneca then took control of the franchise in 2012 when BMS
-
AZ gets limited approval for metreleptin in US
BMS acquired rights to metreleptin when it bought Amylin in 2012. .
-
FDA clears BMS/AZ's dapagliflozin at second attempt
AZ will also have a commanding position in the latter category following the alliance's $7bn acquisition of Amylin in 2012.
-
AstraZeneca buys BMS out of diabetes alliance
Analysts at Panmure Gordon said the deal seemed "sensible", particularly in light of the fact that AZ paid $3.5bn for its 50 per cent share in Amylin alongside BMS last ... year. . AZ now has full control of three Amylin-developed products, namely the
AstraZeneca bullish on diabetes franchise fortunes
FDA approves Lilly’s GLP-1 diabetes drug Trulicity
AZ gets limited approval for metreleptin in US
FDA clears BMS/AZ's dapagliflozin at second attempt
AstraZeneca buys BMS out of diabetes alliance
More from news
Approximately 2 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
Interview: Christopher Boulton, AstraZeneca
This was then expanded in 2012 when the alliance acquired Amylin, gaining the rights to a portfolio of products for type 2 diabetes, including the exenatide franchise (Byetta and Bydureon).
-
Case study: Educating HCPs and patients about diabetes
Campaign:Diabetes Close to the Heart. Timescale:January, 2010 to November, 2010. Chandler Chicco Agency, with Amylin Pharmaceuticals, Inc. ... Extending education beyond the live performance, CCA worked with Amylin to develop filmed adaptations of the
-
Weighty matters
Additionally, the Alliance has grown into a multi-funder initiative and has received funding from Amylin Pharmaceuticals and Allergan.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Adocia names senior members of new US subsidiary
Bruce has also held position at Amylin Pharmaceuticals, where he was in charge of Bydureon's phase III studies and safety analysis, a once weekly GLP-1 injectable formulation. ... Daly's experience in the diabetes field also includes several years at
-
Profil Institute appoints former Amylin CEO
Bradbury is an experienced figure in the life science industry, serving as CEO of Amylin from 2007 to 2012 until its acquisition by Bristol-Myers Squibb.
Adocia names senior members of new US subsidiary
Profil Institute appoints former Amylin CEO
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Publications Director
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
-
Medical Editor
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Account Management
-
Competitive Salary Offered
-
Associate Account Director
-
Competitive Salary
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Senior Medical Writer
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Account Manager
-
Competitive Salary
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
-
Senior Account Executive
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
Create Health
A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
